V Convención de la Profesión Médica

V Convención de la Profesión Médica • Love J. Drug pricing is out of control, what should be done? PLOS blogs. 2015. Lundh A Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. • Mazzucato M. The Entrepreneurial State: Debunking Public vs. Private Sector Myths, Anthem Press. 2011. • Mazzucato M. How taxpayers prop up Big Pharma, and how to cap that. Los Angeles Times. Oct. 27 2015. • Novoa A, Gérvas J, Ponte C. Salvaguardas, deriva institucional e industrias farmacéuticas. AMF. 2014;10 (7):373-82. • OM y COM (2015). Declaración de Lisboa. Ordem dos Medicos de Portugal y Consejo General de Médicos de España. Lisboa, 10-11 Noviembre 2015. Prescrire International. A review of new drugs in 2004: Floundering innovation and increased risk-taking. Prescrire International. 2005;14(76):68-73. • Prescrire Int. New drugs and indications 2010: indadequate assessment; patients at risk. Prescrire Int. 2011;20(115):105-10. http://english.prescrire.org/en/115/446/48385/2403/2399/SubReportDetails.asp x. • SESPAS. TTIP y Salud. Posicionamiento completo SESPAS. Coordinador Álvarez- Dardet C; autores: Umaña R, Cantero J, Cantarero D, Escolar A, Marcilla M. Noviembre 2015. • Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66(9):1909-14. • Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2(5):e138. ´t Hoen E. The Global Politics of Pharmaceutical Monopoly Power. AMB Publishers, The Netherlands. 2009. • ´t Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc. 2011;14:5.